Publications

5674 Results

Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle invasive bladder cancer in SWOG S1314

Authors
Y-T Lu;M Plets;G Morrison;A Cunha;S Cen;S Rhie;K Siegmund;S Daneshmand;D Quinn;S Lerner;D Petrylak;D McConkey;T Flaig;I Thompson;A Goldkorn
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4506), abst 4506; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1314

A Phase III Randomized Trial of Eribulin (E) with or without Gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or Ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClinicalTrials.gov NCT04579224)

Authors
S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;IM Thompson
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4608), poster 94a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1937

Impact of Social Media on the Wellness of Pediatric and Adult Oncologists: A SWOG and COG survey

Authors
S Moerdler;M Barry;E Henry;T Lucas;A Marshall;D Dizon
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 11013), poster 204; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network survey of Oncology Research Professionals

Authors
D Dizon;C Szczepanek;D Petrylak;D Sparks;C Tangen;P Lara;IM Thompson;CD Blanke
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 11049), poster 240; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022

Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Authors
S Halabi;A Roy;L Rydzewska;P Godolphin;M Parmar;M Hussain;C Tangen;I Thompson;W Xie;M Carducci;M Smith;M Morris;G Gravis;D Dearnaley;P Verhagen;T Goto;N James;M Buyse;J Tierney;C Sweeney
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 5006), abst 5006; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221

Authors
C-S Chen;G Zirpoli;S McCann;W Barlow;GT Budd;L Pusztai;G Hortobagyi;A Godwin;A Thompson;C Ambrosone;K Stringer;D Hertz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 12023), poster 269; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Breast
Study Number(s)
S0221

Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements

Authors
K Blenman;K Fanucci;Y Bai;V Pelekanou;Z Nahleh;S Shafi;S Burela;W Barlow;P Sharma;A Thompson;A Godwin;D Rimm;G Hortobagyi;L Pusztai
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 594), poster 365; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Breast
Study Number(s)
S0800

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (SWOG S0931, NCT01120249)

Authors
CW Ryan;C Tangen;E Heath;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;T Synold;M Plets;U Vaishampayan;B Shuch;N Vogelzang;I Thompson;P Lara
Journal / Conference
J Clin Oncol 40, 2022 (suppl 17; abstr LBA4500), abst. LBA4500; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S0931

Follow-Up Analysis of the Randomized Phase II Trial of Bortezomib, Lenalidomide, Dexamthasone with/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (SWOG-1211)

Authors
S Usmani;A Hoering;S Ailawadhi;R Sexton;B Lipe;J Valent;M Rosenzweig;J Zonder;M Dhodapkar;N Callandar;T Zimmerman;P Voorhees;B Durie;V Rajkumar;P Richardson;R Orlowski
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 8054), poster 477; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Myeloma
Study Number(s)
S1211

Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from SWOG S1216, a phase III trial of ADT with or without orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;N Agarwal
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 5071), poster 254; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1216